evipedia.ai
← Back

PEG-MGF for Health & Longevity

Created on 10/26/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5.5 – Audit

PEG-MGF is a synthetic copy of a short protein fragment muscle makes after hard training, with an inert chain attached so it lasts longer, sold as a research chemical and injected for recovery and muscle repair. No study has given it to a person; its cell and animal basis is contested. Risks are unmeasured, not absent: allergic reactions to the coating, tumour links, and mislabelled or contaminated vials. (Full Review)

Protocol

Published dose evidence
None in humans
Only peer-reviewed figures are animal doses; no approval, guideline or label dose exists
Documented self-administration pattern
Roughly 200–400 µg, two to three times weekly
8–16 week blocks; online regimens, not validated and not clinical guidance
Half-life
Unreported for PEG-MGF
Extent of extension by PEGylation undocumented; dosing frequency has no rational basis
Time to effect
Time to effect
Unknowable from evidence
No human outcome measured at any timepoint; claims of benefit within days or weeks rest on expectation

Benefits

Contraindications
  • Active, suspected or recently treated malignancy, and pre-malignant lesions
  • Prior hypersensitivity to a PEGylated drug or PEG-containing vaccine
  • Pregnancy and breastfeeding
  • Adolescents and young adults with open growth plates
  • Untreated proliferative diabetic retinopathy or diabetes with HbA1c above 9%
    •
Key Interactions
Theoretical (inferred from mechanism)
  • Recombinant growth hormone (somatropin, somapacitan)
  • IGF-1 analogues (mecasermin, IGF-1 LR3)
  • Insulin and insulin secretagogues (insulin glargine, glimepiride)
  • Growth hormone secretagogues (ipamorelin, tesamorelin)
  • Other PEGylated injectables (pegfilgrastim, pegloticase)
  • Anabolic-androgenic steroids (testosterone enanthate, nandrolone)
  • Supplements with additive growth-pathway effects (high-dose leucine, colostrum)
  • Supplements affecting glucose (berberine, chromium)
  • Other interventions (heavy resistance training, blood-flow-restriction work)
    •

Risk & Side Effects

  • High:
  • Medium: Anti-PEG Antibody Reactions and Loss of Effect
    •
  • Low: Product Identity, Purity and Sterility Failures; Tumour-Promoting Signalling; Injection-Site and Fluid-Retention Complaints
    •
  • Speculative: Muscle Mass Gained at the Expense of Force; Hypoglycaemia and Insulin-Pathway Overlap
    •

Monitoring

Marker Target Why
Serum IGF-1 Age- and assay-specific laboratory reference interval Index of pathway activation
Fasting glucose 70–99 mg/dL Safety check: glucose lowering
HbA1c 4.0–5.6% Safety check: abnormal blood sugar control
PSA (men) No established target; track change from own baseline Safety check: prostate tumour link

Cadence: Baseline before any exposure; glucose markers at 4 weeks, then every 3 months; IGF-1 at 3 months, then every 6 months; PSA annually in men

Qualitative Assessment

  • Injection-site appearance: redness, firmness, swelling or lumps
  • Perceived recovery between training sessions, and soreness duration
  • Joint and muscle aching; ring, shoe or facial tightness suggesting fluid retention
  • Appetite change, and symptoms of low blood sugar such as shakiness or sweating
  • Sleep quality and daytime energy, as a change-from-baseline signal
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.